Cabiralizumab

Drug Profile

Cabiralizumab

Alternative Names: BMS-986227; FPA-008

Latest Information Update: 10 Jun 2017

Price : $50

At a glance

  • Originator Five Prime Therapeutics
  • Developer Bristol-Myers Squibb; Five Prime Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Colony stimulating factor receptor antagonists; Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pigmented villonodular synovitis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pigmented villonodular synovitis
  • Phase I Solid tumours
  • Preclinical Cancer
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 04 Jun 2017 Interim safety and efficacy data from a phase I/II trial in Pigmented villonodular synovitis released by Five Prime Therapeutics
  • 19 May 2017 Bristol-Myers Squibb and Ono Pharmaceutical plan the phase I trial for Cancer (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV) (NCT03158272)
  • 04 May 2017 Five Prime Therapeutics plans a pivotal trial expected to initiate in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top